Eli Lilly launches digital healthcare process
Betsy Goodfellow | January 5, 2024 | News story | Medical Communications |Â Â Diabetes, Eli Lilly, Obesity, diabetes, obesityÂ
Eli Lilly has announced its new digital healthcare experience, LillyDirect, which will benefit patients in the US with obesity, migraine and diabetes. This is intended to offer resources around disease management, such as access to healthcare providers, tailored support and delivery of selected medications.
The programme will provide patients with LillyDirect Pharmacy Solutions, a digital pharmacy for select Lilly medications utilising third party online pharmacy fulfillment services; disease and healthcare educational information; access to telehealth providers; and an independent search tool allowing patients to access healthcare professionals near then.
David A Ricks, Lilly’s chair and chief executive officer, commented: “A complex U.S. healthcare system adds to the burdens patients face when managing a chronic disease. With LillyDirect, our goal is to relieve some of those burdens by simplifying the patient experience to help improve outcomes. LillyDirect offers more choices in how and where people access healthcare, including a convenient home delivery option to fill Lilly medicines they have been prescribed.”
Frank Cunningham, group vice president, global value and access at Lilly, added: “We know that people have come to depend on the efficiency and convenience of digital solutions to meet a variety of their everyday needs – healthcare being one of them. We launched LillyDirect with the hope that it will offer patients an innovative end-to-end experience to manage their health and access their medicines, so they can get back to living their lives.”
Betsy Goodfellow
Related Content
Lilly opens fourth US Gateway Labs site
Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …
FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as …
Lilly reports positive results from trial of obesity candidate
Eli Lilly and Company (Lilly) has announced topline results from its phase 3 ATTAIN-1 trial, …
